1887
Rapid communications Open Access
Like 0

Abstract

Australian and New Zealand health authorities identified seasonal trivalent inactivated influenza vaccines manufactured by CSL Biotherapies as the probable cause of increased febrile convulsions in children under five within 24 hours of vaccination and recommended against their use in this age group. We quantified the benefit-risk profile of the CSL vaccines using the number needed to vaccinate and suggest they might have caused two to three hospital admissions due to febrile convulsions for every hospital admission due to influenza prevented.

Loading

Article metrics loading...

/content/10.2807/ese.15.37.19661-en
2010-09-16
2017-12-12
http://instance.metastore.ingenta.com/content/10.2807/ese.15.37.19661-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/15/37/art19661-en.htm?itemId=/content/10.2807/ese.15.37.19661-en&mimeType=html&fmt=ahah
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error